Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 6Unknown 5Terminated 5Recruiting 3Active not recruiting 3Not yet recruiting 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Thoracic 5

Conditions

Breast Neoplasms 1841Neoplasms 1230Colorectal Neoplasms 1046Carcinoma, Non-Small-Cell Lung 996Stomach Neoplasms 787Carcinoma, Hepatocellular 780Lung Neoplasms 756Prostatic Neoplasms 682Pancreatic Neoplasms 567Rectal Neoplasms 444Colonic Neoplasms 401Neoplasm Metastasis 400Ovarian Neoplasms 399Uterine Cervical Neoplasms 395Recurrence 380Leukemia, Myeloid, Acute 367Esophageal Neoplasms 352Multiple Myeloma 340Lymphoma 330Head and Neck Neoplasms 326Melanoma 306Precursor Cell Lymphoblastic Leukemia-Lymphoma 288Brain Neoplasms 263Urinary Bladder Neoplasms 249Nasopharyngeal Carcinoma 221Liver Neoplasms 221Leukemia 217Lymphoma, Large B-Cell, Diffuse 213Polycystic Ovary Syndrome 206Squamous Cell Carcinoma of Head and Neck 200

Interventions

surufatinib 1pemigatinib 1Vinorelbine 1Pemetrexed 1Drug Therapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Advanced Non-Small Cell Lung Cancer × Clear all
NCT04922658 2024-07-31

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Phase 2 Unknown
60 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

NCT06174857 2023-12-18

Efficacy of Osimertinib in Patients With Lung Cancer

Hunan Province Tumor Hospital

Unknown
100 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

NCT05978401 2023-08-07

Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer

Guangzhou Gloria Biosciences Co., Ltd.

Phase 1/2 Unknown
152 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

NCT05287386 2022-03-18

A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

The First Affiliated Hospital of Xiamen University

Phase 2 Unknown
20 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

NCT00786331 2009-08-03

Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2 Unknown
230 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡